Skip to main content
padlock icon - secure page this page is secure

Hypertensive Pharmacogenomics in African Americans

Buy Article:

$68.00 + tax (Refund Policy)

Hypertension affects 60 million Americans and is the most common disorder for which medications are prescribed in the USA. Hypertension associates with serious complications including stroke, heart failure, ischemic heart disease, and renal failure. Racial background associates with the prevalence and complications of hypertension with African Americans more frequently and severely affected. Hypertensive African Americans demonstrate different responses to antihypertensive medications compared to other ethnic groups and specific candidate gene polymorphisms associate with the responses found.

Differences between African Americans and other racial groups are present with regard to endothelial dysfunction and activation of the renin-angiotensin-aldosterone system. In addition the frequency of polymorphisms of genes involved in the regulation of endothelial function and the renin-angiotensin-aldosterone system differ between African Americans and other ethnic groups. This review highlights the current information available with regard to the genetics of hypertension in African Americans with particular attention to pharmocogenomic studies of antihypertensive therapy.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: angiotensin II type 1 receptor gene (AGTR1); angiotensin converting enzyme inhibitors (ACEI); antihypertensive therapy; blood pressure; gene polymorphism; hydrochlorothiazide

Document Type: Review Article

Affiliations: Emory University School of Medicine, 1639 Pierce Drive, WMB 338, Atlanta, GA 30322.

Publication date: December 1, 2005

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more